Objectives: The time to positivity (TTP) of blood cultures is associated with the microbial load in the blood and prognosis in patients with bloodstream infections caused by various bacterial species. However, relevant information about the TTP for Candida species in candidaemia is limited. We investigated the clinical impact of the TTP on mortality in patients with candidaemia.
Introduction
Candida species are an increasing cause of nosocomial bloodstream infections among critically ill patients. Invasive candidiasis, including candidaemia, has a significant impact on patient outcomes. Despite medical advances over the past several decades, the mortality rate for candidaemia remains high at 35% -60%. 1 -3 To date, conventional culture-based microbiological methods have served as the cornerstone for the diagnosis of candidaemia in clinical practice. In most cases of candidaemia, the report of a positive blood culture for yeast leads clinicians to begin antifungal therapy. Consequently, a shorter time to positivity (TTP) could lead to the earlier administration of antifungal agents. The time to initiation of appropriate antifungal therapy (AAT) can have a significant impact on clinical outcomes. Several studies have demonstrated that delays in the start of effective antifungal therapy in cases of candidaemia resulted in a higher mortality rate compared with patients who received therapy in a more timely manner. 4 -6 The TTP of blood cultures is known to be related to the bacterial concentration in the blood. 7 Previous studies have suggested an association between a short TTP and poor prognosis in patients with bacteraemia caused by various bacterial species. 8 -13 However, data on the relationship between the TTP for Candida species and clinical outcomes of candidaemia are lacking. Furthermore, the TTP and timing of antifungal therapy could influence each other. We investigated the impact of TTP on clinical outcomes in patients with candidaemia.
Patients and methods

Hospital setting
This study was conducted at a university-affiliated, tertiary hospital with 950 beds, including 56 beds in three intensive care units (ICUs), located in Seoul, South Korea. Blood cultures were performed in patients with signs or symptoms of infection as routine practice. In patients with a positive culture for yeast, blood cultures were usually repeated every 3 days until negative or when indicated clinically. At least two sets of blood samples were obtained for blood culture from separate venepunctures. If a central venous catheter (CVC) was present, a blood culture set could be replaced by a blood sample drawn through the catheter. Each set of blood samples was inoculated into one aerobic and one anaerobic bottle and immediately loaded into a BacT/ALERT w 3D Microbial Detection System (bioMérieux, Inc., Durham, NC, USA). Candida species identification was done using the automated Vitek w 2 Yeast Biochemical Card (bioMérieux, Inc.). Since January 2011, our institution has routinely performed antifungal susceptibility testing of all Candida species isolated from blood cultures using the AST-YS01 card (bioMérieux, Inc.), which is designed to test susceptibility to amphotericin B, fluconazole, flucytosine and voriconazole, according to the manufacturer's instructions. The interpretation of susceptibility was based on the MIC breakpoints recommended in the M27-S3 supplement of the CLSI.
14 CVC removal was considered in all patients with documented candidaemia, if at all possible. This study was approved by the Institutional Review Board of Korea University's Anam Hospital. Informed consent was not required by the board because of the retrospective design of the study.
Study design
A retrospective case-control study was designed to assess the clinical impact of TTP on mortality in patients with candidaemia. Over a 6 years period (January 2006 through to July 2012), all consecutive hospitalized patients ≥18 years of age with candidaemia were eligible for inclusion. The following data were collected for each patient from the hospital's electronic medical records: demographics, comorbidities, risk factors for candidaemia, severity of illness, clinical characteristics of candidaemia episodes, antifungal therapy and 6 week mortality. All patients were followed for up to 100 days after the onset of candidaemia or until loss to follow-up or death from any cause.
Definitions
Candidaemia was defined as at least one peripheral blood culture positive for Candida species obtained from patients with compatible clinical signs or symptoms. For each patient, only the first episode of candidaemia caused by the same Candida species was recorded. The time of onset of candidaemia was defined as the time of sampling for the first positive blood culture. The Charlson comorbidity index was used to assess the impact of multiple comorbidities. 15 We recorded the risk factors for candidaemia within 30 days prior to the first positive blood culture. Neutropenia was defined as an absolute neutrophil count of ,500 cells/mm 3 . The definitions of severe sepsis and septic shock were adapted from the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. 16 The severity of illness at the onset of candidaemia was assessed using the sequential organ failure assessment (SOFA) score and the Pitt bacteraemia scoring system. 17, 18 The source of infection was established based on clinical evidence of infection, regardless of whether causative organisms were recovered from the origin. A catheter-related bloodstream infection was defined according to the guidelines of the Infectious Diseases Society of America. 19 The gastrointestinal tract was considered as the source of candidaemia if patients had signs or symptoms related to the gastrointestinal tract prior to the onset of candidaemia and did not have any other source, using the previous definition with minor modifications. 20 The TTP was determined from the time interval between the start of incubation and the detection of microbial growth in peripheral blood, as documented using an automated monitoring system. 21 The timing of AAT was defined as the interval between the onset of candidaemia and the administration of AAT. The appropriateness of antifungal therapy was based on the results of susceptibility testing, if available. Appropriate doses of antifungal agents were determined based on the Infectious Diseases Society of America guidelines as follows: fluconazole, loading dose of 800 mg (12 mg/kg) followed by 400 mg (6 mg/kg) once daily for all Candida species except Candida glabrata (for fluconazole-susceptible dosedependent isolates or C. glabrata without susceptibilities, ≥800 mg once daily); amphotericin B deoxycholate, 0.5-1.0 mg/kg once daily; liposomal amphotericin B, 3 -5 mg/kg once daily; caspofungin, loading dose of 70 mg followed by 50 mg once daily; anidulafungin, loading dose of 200 mg followed by 100 mg once daily; micafungin, 100 mg once daily; and voriconazole, loading dose of 400 mg (6 mg/kg) twice daily for two doses followed by 200 mg (3 mg/kg) twice daily. 22 For patients with a calculated creatinine clearance of ≤50 mL/min, 50% of the usual dose of fluconazole was considered appropriate. Fluconazole was assumed to be inappropriate for the treatment of candidaemia due to Candida krusei. Persistent candidaemia was defined as persistently positive blood cultures for the same Candida species for ≥7 days after the initiation of AAT. Early CVC removal meant removal within 48 h of drawing the first blood sample that was culture positive for a Candida species. 23 If the CVC was removed at a later time, reinserted or exchanged over a guidewire, it counted as CVC retention.
Statistical analysis
Continuous variables represented the medians and IQR. The x 2 test or Fisher's exact test was used to compare categorical variables. Student's t-test or one-way ANOVA with post hoc Scheffé tests was used to compare continuous variables. The cut-off value of the TTP for catheterrelated candidaemia was derived by a receiver operating characteristic (ROC) curve analysis. Simple linear regression analysis was used to evaluate the association between the TTP and the timing of AAT. Cox regression analysis for the predictors of mortality was performed. All significant variables associated with mortality in the univariate analysis were entered into the multivariable model. Kaplan-Meier survival estimates were used to generate survival curves and differences between the survival curves were assessed by means of the log-rank test. Two-sided P values ,0.05 were considered to indicate statistical significance. All statistical analyses were performed using SPSS version 15.0 (SPSS Korea, Seoul, Korea).
Results
Patient characteristics
During the study period, we identified a total of 152 patients with significant candidaemia. No cases had candidaemia caused by two or more Candida species. The incidence of candidaemia was 29 cases per 1000 patient-years. Among all episodes of candidaemia, 82 (54%) developed in patients hospitalized on the wards and 64 (42%) in patients in an ICU. Six (4%) occurred at the time of the emergency room visit.
The median age of the study patients was 68 years (IQR 57 -75 years) and 57% were male (Table 1) . Solid tumour (48%) and diabetes mellitus (30%) were the most common comorbidities. The gastrointestinal tract (38%) and CVC (36%) were major sources of candidaemia. The most commonly isolated Candida species was Candida albicans (44%), followed by Candida tropicalis (22%), Candida parapsilosis (18%) and C. glabrata (11%). CVC was a more frequent source of infection in candidaemia caused by C. tropicalis than in that caused by C. glabrata (42% versus 11%, P ¼ 0.030). Antifungal susceptibility profiles were available for 21% (32/152) of the Candida isolates, including 16 C. albicans, 9 C. tropicalis, 5 C. glabrata and 2 C. parapsilosis. Most of these were susceptible to all of the tested antifungal drugs except for one C. albicans isolate (susceptible in a dose-dependent fashion to fluconazole) and one C. glabrata isolate (resistant to fluconazole). Of 152 patients, 113 (74%) received antifungal therapy Time to positivity and mortality in candidaemia 
TTP for Candida isolates
The median TTP for all Candida isolates was 27 h (IQR 19-37 h). Among a total of 152 isolates, 65 (43%) showed a TTP of ≤24 h. The TTP of each Candida species was significantly different [median (IQR)]: 18.5 h (12 -21 h) for C. tropicalis; 27 h (21 -34 h) for C. albicans; 32 h (20.5-35.5 h) for C. parapsilosis; 50 h (48-76 h) for C. glabrata; and 23 h (10-26 h) for other Candida species (P,0.001 for intergroup difference). Post hoc tests indicated a significantly longer TTP for C. glabrata than that for non-glabrata Candida species (P,0.001).
The TTP was significantly shorter in patients with catheterrelated candidaemia than in those with a non-catheter source of candidaemia [median (IQR) 23 h (11-32 h) versus 29 h (21-45 h), P ¼ 0.012]. By ROC curve analysis, the cut-off value of the TTP for catheter-related candidaemia was 22 h, with an area under the curve of 0.67 (sensitivity 54% and specificity 32%, P ¼ 0.002). Following adjustment for the source of candidaemia, the frequency of a TTP of ≤24 h was significantly different among Candida species (P, 0.001).
In a simple linear regression analysis, the timing of AAT was significantly correlated with TTP according to the following equation: predicted timing of AAT (h) ¼ 12.458 +1.987×TTP (h) (r¼ 0.527, P,0.001). Only eight patients (8%, 8/98) were receiving antifungal therapy prior to a positive blood culture. The median delay time from a positive blood culture to the start of AAT was 28 h (IQR 14 -46 h).
Clinical outcomes and predictors of mortality
Persistent candidaemia was observed in 14 (17%) of 83 patients who received AAT for .7 days. Among 14 patients with persistent candidaemia, 10 (71%) failed in early CVC removal. The proportion of persistent candidaemia was not significantly different between early CVC removal and CVC retention (11% versus 22%, P¼0.244). Neither a short TTP (≤24 h) nor delays in the initiation of AAT (.72 h) was associated with persistent candidaemia (21% versus 14%, P¼0.538 and 19% versus 15%, P¼0.764, respectively).
The overall mortality rate at 6 weeks was 53% (81/152) of all candidaemic patients. The median time of death was 7 days (IQR 4 -14 days) after the onset of candidaemia. A comparison of the characteristics of the patients in the survivor and nonsurvivor groups is shown in Table 1 . The two groups based on survival at 6 weeks did not differ significantly in terms of demographic characteristics, comorbidities, prior hospital stay, source of candidaemia and distribution of Candida species. The non-survivors showed a significantly higher Charlson comorbidity index value, SOFA score and Pitt bacteraemia score. With regard to risk factors for a Candida infection, non-survivors were more likely to stay in the ICU at the onset of candidaemia, and to receive corticosteroids, total parenteral nutrition and mechanical ventilation and have no prior history of surgery. Use of first-line antifungal agents differed significantly between the survivors and non-survivors: fluconazole therapy was more frequently administered to survivors (P,0.001) and the proportion of patients with no antifungal therapy was higher in non-survivors (P,0.001).
Figure 1(a) shows the mean TTP and 95% CI for four groups of patients based on the timing of AAT. A significant difference in the mean TTP between the four groups was found as follows: 15 h, AAT,24 h; 22 h, AAT 24 -48 h; 30 h, AAT 48 -72 h; and 36 h, AAT .72 h (P,0.001). Overall, the 6 week mortality rate was significantly different between the groups based on the timing of AAT (P ¼ 0.016, Figure 1b) . As compared with the .72 h group (64%, 58/91), the mortality rates were significantly lower in the 24 -48 h group (41%, 13/32) and in the 48 -72 h group (33%, 7/21) (P ¼0.037 and P ¼ 0.014, respectively). The mortality rate in the ,24 h group (38%, 3/8) was not significantly different from that in the .72 h group (P ¼0.254).
The mortality rate at 6 weeks was significantly higher in the group with a TTP ≤24 h than in the group with a TTP .24 h (65% versus 45%, P ¼ 0.021) and in the group with AAT .72 h than in the group with AAT ≤72 h (64% versus 38%, P ¼ 0.002), respectively. Kaplan -Meier estimates of survival based on the TTP and timing Candida famata (n ¼3), Candida guilliermondii (n¼2), Candida lusitaniae (n ¼1) and Candida sphaerica (n¼1). c Caspofungin (n ¼3), anidulafungin (n¼2) and micafungin (n¼1). d Includes the number of patients who received no AAT.
Time to positivity and mortality in candidaemia 2893 JAC of AAT are shown in Figure 2 . There were significant differences in survival between TTP ≤24 and .24 h (P ¼ 0.007, Figure 2a ) and between the timing of AAT ≤72 and .72 h (P ¼ 0.001, Figure 2b ). Univariate and multivariate Cox regression analyses were performed to determine the predictive factors for the 6 week mortality in all patients with candidaemia. In the univariate analysis, an increased Charlson comorbidity index value, ICU residence at the onset of candidaemia, predisposing factors for Candida infection within 30 days prior to candidaemia (corticosteroids, surgery, total parenteral nutrition and mechanical ventilation), higher severity of illness (presentation of severe sepsis or septic shock and SOFA score), TTP ≤24 h, timing of AAT .72 h, persistent candidaemia and CVC retention were significantly associated with the 6 week mortality rate ( 
Discussion
Candidaemia was associated with a mortality of ≥50% among the study patients. We investigated the relationship between TTP and the timing of antifungal therapy and the impact of TTP for Candida isolates on clinical outcomes in patients with candidaemia. The TTP was significantly different among Candida species (C. glabrata versus non-glabrata Candida species) and between sources of candidaemia (catheter versus non-catheter). There was a moderately positive correlation between TTP and the start time of antifungal therapy. We found that a short TTP (≤24 h) and delays in the initiation of AAT (.72 h) were independent predictors of the 6 week mortality rate.
To date, there is a controversy about the impact of timing of AAT on clinical outcomes. Several studies have demonstrated that early initiation of antifungal therapy decreased the length of time in the ICU or hospital mortality. 4, 6, 24 They suggested that the earlier Kim et al.
antifungal therapy was administered after the onset of candidaemia, the greater the number of patients that survived. However, other studies failed to find benefits of an earlier start of antifungal therapy in terms of clinical outcomes. 25 -27 Although no reason for the discrepancy was provided, the results presented in those studies could have been influenced by various factors, including the study design, study populations, practical strategy and method of data analysis. Our data suggest that delayed initiation of antifungal therapy was significantly associated with increased mortality, even though earlier antifungal therapy was not found to have any benefit among patients who received it within 72 h. It is noteworthy that we conducted this study considering not only the timing of AAT, but also the concept of TTP for Candida species.
Data regarding the TTP for Candida species are limited. 21, 28, 29 Ben-Ami et al. 29 first described the utility of TTP for the diagnosis of catheter-related candidaemia. They concluded that a TTP of ≤30 h was a sensitive (100%) but non-specific (51%) indicator of an intravascular catheter as the source of candidaemia. Our study also showed a significant difference in TTP between catheterrelated and non-catheter-related candidaemia, although the cut-off value of TTP was lower than in previous studies. This time gap could be a result of the distribution of Candida species and variations in factors related to blood cultures in clinical practice. Recently, Lai et al. 21 demonstrated the utility of TTP for the earlier differentiation of Candida species. Their findings (namely, the shortest TTP for C. tropicalis and the longest for C. glabrata) are consistent with our results. Furthermore, the statistical significance of the interspecies difference in TTP in this study remained after the analysis was adjusted for the source of infection.
To date, only one study by Taur et al. 28 has demonstrated the impact of TTP on clinical outcome. The study investigated the associations between three separate time periods, from blood culture collection to the initiation of antifungal therapy and hospital mortality, in cancer patients with candidaemia. 28 Among the incubation period, provider notification period and antifungal initiation period, the incubation period was considered to be synonymous with TTP in our study. Taur et al. 28 found that only a longer Time to positivity and mortality in candidaemia 2895 JAC incubation period was significantly associated with higher mortality by multivariate analysis. This result conflicts with our data as well as previous findings regarding the TTP of bacterial bloodstream infections. 8 -13 Taur et al. 28 reported several potential confounding variables that affected the results, including the aetiologies of candidaemia, general patient health, volume of blood inoculated into the culture bottles and different Candida species. However, considering the fact that TTP is a surrogate marker of microbial load, it is difficult to accept the argument suggested by Taur et al. 28, 30 Based on our research, it is presumed that the incubation period could be misinterpreted as a significant predictor of mortality instead of the total time period, because it accounted for most of the total time period (time from blood culture collection to antifungal initiation) in their data. In our study, antifungal therapy was started with a longer delay after the detection of yeast in the blood culture (median 28 versus 7.8 h) and thus the impact of each time period on mortality could be more clearly demonstrated. As a result, we found that the total time period was a major determinant of mortality, whereas a short incubation period was independently associated with increased mortality despite early initiation of antifungal therapy.
To our knowledge, this is the first report that a short TTP is an independent predictor for mortality in patients with candidaemia. However, this study had several potential limitations. First, this was a retrospective study from a single, university-based population. The patients' characteristics, distribution of Candida species and policy for the treatment of candidaemia at our institution may have influenced the results. Although these factors were adjusted with the use of multivariate Cox regression analysis, the epidemiological characteristics of candidaemia in South Korea, especially the high proportion (22%) of C. tropicalis, may be a main factor affecting the results. Second, the study included a relatively small number of cases caused by each Candida species and subgroup analysis was performed. Third, antifungal susceptibility test results were available for only 21% of the isolates, because antifungal susceptibility testing for Candida species started from January 2011 as a part of routine practice in our institution and there is a chance of error in the appropriateness of antifungal therapy. However, on the basis of recent nationwide data on antifungal susceptibility among Candida bloodstream isolates, we attempted to minimize any misinterpretation. 31 In conclusion, candidaemia was persistently responsible for high mortality rates in critically ill patients. We found that a short TTP in patients with candidaemia was a significant predictor of mortality in addition to multiple comorbid diseases, severity of illness at the onset of candidaemia, delayed initiation of AAT and persistent candidaemia. Our results suggest that earlier antifungal therapy based on efficient clinical selection strategies with new non-culturebased microbiological assays are required to improve the clinical outcome in patients with higher-load candidaemia. To clarify the relationship between the blood fungal load, TTP and clinical outcomes of candidaemia and to expand the application of our results, additional studies using an in vitro or animal model system as well as large-scale, multicentre clinical data are needed.
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